Table 1 Patient characteristics by treatment arm.

From: Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Factor

All patients

RD

VRd

P-value

Age ≥ 65 yr

197/460 (43%)

106/225 (47%)

91/235 (39%)

0.074

Female

191/460 (42%)

105/225 (47%)

86/235 (37%)

0.030

SWOG performance status > 1

53/441 (12%)

29/216 (13%)

24/225 (11%)

0.384

sb2m ≥ 3.5 mg/L

284/458 (62%)

143/224 (64%)

141/234 (60%)

0.442

CRP ≥ 8 mg/L

125/443 (28%)

65/219 (30%)

60/224 (27%)

0.527

Creatinine ≥ 2 mg/dL

21/460 (5%)

10/225 (4%)

11/235 (5%)

1.000

LDH ≥ 190 U/L

163/454 (36%)

81/223 (36%)

82/231 (35%)

0.922

Albumin < 3.5 g/dL

196/458 (43%)

97/223 (43%)

99/235 (42%)

0.778

Hb < 10 g/dL

147/460 (32%)

70/225 (31%)

77/235 (33%)

0.764

Platelet count < 150 × 109/L

80/460 (17%)

45/225 (20%)

35/235 (15%)

0.176

ISS Stage III

155/460 (34%)

78/225 (35%)

77/235 (33%)

0.694

Intent to transplant

315/460 (68%)

153/225 (68%)

162/235 (69%)

0.841

  1. n/N (%): n—Number with factor, N—Number with valid data for factor.
  2. ND: No valid observations for factor.
  3. P-values computed using Fisher’s exact test.
  4. P-values represent a comparison between groups, not against the overall population.
Back to article page